The synthetic compound, known as UKH-1114, acts on a previously unknown pathway and works at a much lower dose, with longer duration of action, researchers said.
The pain reliever is as effective at relieving neuropathic pain in injured mice as a drug widely used for pain relief called gabapentin, they said.
Neuropathic pain, or chronic pain, is caused when nerves in the central nervous system are damaged.
"If the drug is safe, effective and nonaddictive in humans - a process that typically takes years - the discovery could be instrumental in addressing one of today's biggest public health challenges: the opioid abuse epidemic," said Stephen Martin from The University of Texas at Austin in the US.
"This opens the door to having a new treatment for neuropathic pain that is not an opioid. And that has huge implications," said Martin.
The pain drug they found binds to a receptor on cells throughout the central nervous system called the sigma 2 receptor. Although it was discovered 25 years ago, scientists still did not know what sigma 2 did until now.
Theodore Price, associate professor at The University of Texas at Dallas, tested UKH-1114 on mice with nerve damage and found that it alleviated pain as well as gabapentin did, but at a much lower dose (one-sixth as much) and was effective much longer (lasting for a couple of days, compared with 4 to 6 hours).
The study was published in the journal ACS Chemical Neuroscience.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
